PubRank

Shimon Slavin

Author PubWeight™ 122.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009 8.20
2 Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002 6.46
3 Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009 6.22
4 Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010 4.03
5 Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009 3.89
6 Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2007 3.00
7 Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 2007 2.63
8 The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult Scler 2010 2.45
9 Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009 2.43
10 Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008 1.84
11 Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2002 1.74
12 MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 2013 1.64
13 Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006 1.62
14 Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 2002 1.54
15 Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008 1.51
16 Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2005 1.45
17 Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent. Haematologica 2005 1.40
18 The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006 1.34
19 Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012 1.23
20 Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget 2013 1.22
21 A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant 2009 1.22
22 Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 2007 1.17
23 MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One 2013 1.15
24 Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 2002 1.12
25 Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica 2008 1.11
26 Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol 2008 1.10
27 Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 2007 1.09
28 CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann N Y Acad Sci 2007 1.08
29 Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. EMBO Mol Med 2012 1.04
30 Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond--the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2006 1.03
31 Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J Clin Oncol 2013 1.03
32 A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2006 1.02
33 Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 2008 1.00
34 Risks of immune system treatments. Science 2010 1.00
35 A retrospective review of the outcome after second or subsequent allogeneic transplantation. Biol Blood Marrow Transplant 2009 1.00
36 Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol 2006 0.99
37 Low-dose gamma-irradiation promotes survival of injured neurons in the central nervous system via homeostasis-driven proliferation of T cells. Eur J Neurosci 2004 0.97
38 Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. PLoS One 2010 0.95
39 Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions. Cell Signal 2011 0.93
40 Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells. Exp Hematol 2005 0.92
41 Conversion of red bone marrow into yellow - Cause and mechanisms. Med Hypotheses 2007 0.89
42 Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis. Mol Immunol 2010 0.89
43 Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 2005 0.89
44 ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients. Biol Blood Marrow Transplant 2008 0.88
45 CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy. Biol Blood Marrow Transplant 2008 0.88
46 Intra-arterial catheter directed therapy for severe graft-versus-host disease. Br J Haematol 2002 0.87
47 Preimplantation factor (PIF) analog prevents type I diabetes mellitus (TIDM) development by preserving pancreatic function in NOD mice. Endocrine 2011 0.87
48 Preimplantation factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model. J Neurol Sci 2011 0.87
49 Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 2003 0.86
50 Repair of bone defect using bone marrow cells and demineralized bone matrix supplemented with polymeric materials. Curr Stem Cell Res Ther 2010 0.86
51 The hematological etiology of osteoporosis. Med Hypotheses 2006 0.85
52 Neuroprotection in multiple sclerosis. Clin Neurol Neurosurg 2006 0.85
53 Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2011 0.85
54 The oxidative status of blood cells in a murine model of graft-versus-host disease. Ann Hematol 2007 0.85
55 Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Int J Hematol 2002 0.84
56 Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother 2004 0.83
57 Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experience. Int J Cancer 2010 0.83
58 Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 2002 0.83
59 Fibrin microbeads for isolating and growing bone marrow-derived progenitor cells capable of forming bone tissue. Tissue Eng 2002 0.83
60 Hematopoietic stem cell therapy for malignant diseases. Ann Med 2007 0.82
61 Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy. Am Heart J 2005 0.82
62 Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation. Clin Infect Dis 2004 0.82
63 Heparanase promotes engraftment and prevents graft versus host disease in stem cell transplantation. PLoS One 2010 0.82
64 New insights into the pathophysiology of gastrointestinal graft-versus-host disease using capsule endoscopy. Haematologica 2005 0.82
65 Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production. Diabetes Metab Res Rev 2008 0.82
66 Osteoporosis of hematologic etiology. Exp Hematol 2007 0.82
67 Effect of KRN7000 on induced graft-vs-host disease. Exp Hematol 2004 0.82
68 Split immunity: immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells. J Immunol 2011 0.82
69 New Developments in the Therapy of Acute Myelocytic Leukemia. Hematology Am Soc Hematol Educ Program 2000 0.81
70 Spinal epidural lipomatosis following haploidentical allogeneic bone marrow transplantation for non-Hodgkin lymphoma. Clin Transplant 2004 0.81
71 A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients. Haematologica 2006 0.81
72 Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products. Springer Semin Immunopathol 2004 0.81
73 Non-myeloablative stem cell transplantation for autoimmune diseases. Springer Semin Immunopathol 2004 0.81
74 Reconstruction of cartilage, bone, and hematopoietic microenvironment with demineralized bone matrix and bone marrow cells. Stem Cells 2003 0.81
75 Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 2004 0.80
76 Development of secondary anaplastic oligoastrocytoma after matched unrelated bone marrow transplantation in a child with acute myeloid leukemia. Acta Haematol 2003 0.80
77 Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 2005 0.79
78 In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency. J Allergy Clin Immunol 2011 0.79
79 Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. Exp Hematol 2004 0.79
80 Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. Exp Hematol 2008 0.79
81 Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th(2) shift on autoimmune and anti-inflammatory processes. Cytokine 2002 0.78
82 Telomerase activity and expression in adult human mesenchymal stem cells derived from amyotrophic lateral sclerosis individuals. Cytotherapy 2009 0.78
83 IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy. Biol Blood Marrow Transplant 2012 0.78
84 Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect. Biol Blood Marrow Transplant 2004 0.77
85 Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen. Clin Transplant 2005 0.77
86 Post-hematopoietic stem cell transplantion immune-mediated cytopenias. Immunotherapy 2009 0.77
87 The effect of pegylated antisense acetylcholinesterase on hematopoiesis. Oligonucleotides 2003 0.77
88 A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation. J Immunother 2010 0.77
89 Introduction into PPPM as a new paradigm of public health service: an integrative view. EPMA J 2012 0.77
90 Irradiated mononuclear cells express significant in vitro cytotoxic activity: promise for in vivo clinical efficacy of irradiated mismatched donor lymphocytes infusion. Immunotherapy 2014 0.77
91 CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice. Isr Med Assoc J 2008 0.76
92 Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial. Clin Ther 2004 0.76
93 Interleukin 2 regulation following semi-allogeneic bone marrow transplantation in mice. Cancer Immunol Immunother 2006 0.76
94 Synthetic, non-natural analogs of ceramide elevate cellular ceramide, inducing apoptotic death to prostate cancer cells and eradicating tumors in mice. Cancer Invest 2010 0.76
95 Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients. Exp Hematol 2007 0.76
96 Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells. Cancer Immunol Immunother 2003 0.76
97 CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells. Exp Hematol 2003 0.76
98 Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators. Biol Blood Marrow Transplant 2009 0.75
99 Protective role of bone marrow cells in controlling alloreactivity. Transplantation 2003 0.75
100 Visualization of immune response kinetics in full allogeneic chimeras. Am J Blood Res 2011 0.75
101 Non-myeloblative stem-cell transplantation for immunotherapy of cancer and non-malignant diseases with allogeneic lymphocytes. Isr Med Assoc J 2002 0.75
102 Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease. Cancer Res 2005 0.75
103 Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients. Blood Cells Mol Dis 2004 0.75
104 Depletion of alloreactive T cells for tolerance induction in a recipient of kidney and hematopoietic stem cell transplantations. Pediatr Transplant 2012 0.75
105 A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation. Exp Hematol 2004 0.75
106 Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer. Cytokines Cell Mol Ther 2002 0.75
107 Linomide administration following bone marrow transplantation in mice. Cancer Immunol Immunother 2002 0.75
108 N-acetylcysteine mildly inhibits the graft-vs.-leukemia effect but not the lymphokine activated cells (LAK) activity. Transpl Immunol 2006 0.75
109 Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures. J Neurol Sci 2004 0.75
110 A method for isolating pluripotent/multipotent stem cells from blood by using the pluripotent and germ-line DAZL gene as a marker. Stem Cells Dev 2009 0.75
111 Improved survival following induction of GVHD following lipopolysaccharide immunization. Exp Hematol 2006 0.75
112 SUCCESSFUL TREATMENT OF DIABETES IN NOD MICE WITH ADVANCED DISEASE BY ISLET ISOGRAFTS FOLLOWING IMMUNOREGULATION WITH LINOMIDE (QUINOLINE-3-CARBOXAMIDE). Cell Transplant 1996 0.75
113 Immunoregulation of GVHD by triggering the innate immune system with CpG. Expert Rev Hematol 2009 0.75
114 Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts. Springer Semin Immunopathol 2004 0.75
115 Biological response modifiers as adjuncts to stem cell transplantation. Expert Opin Biol Ther 2006 0.75